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Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative pathology whose molecular etiopathogenesis is not known.
Novel contributions have come from familial forms of PD caused by alterations in genes with apparently unrelated
physiological functions. The gene coding for alpha-synuclein (a-syn) (PARK1) has been investigated as a-syn is located in
Lewy bodies (LB), intraneuronal inclusions in the substantia nigra (SN) of PD patients. A-syn has neuroprotective chaperone-
like and antioxidant functions and is involved in dopamine storage and release. DJ-1 (PARK7), another family-PD-linked gene
causing an autosomal recessive form of the pathology, shows antioxidant and chaperone-like activities too.
Methodology/Principal Findings: The present study addressed the question whether a-syn and DJ-1 interact functionally,
with a view to finding some mechanism linking DJ-1 inactivation and a-syn aggregation and toxicity. We developed an in
vitro model of a-syn toxicity in the human neuroblastoma cell line SK-N-BE, influencing DJ-1 and a-syn intracellular
concentrations by exogenous addition of the fusion proteins TAT-a-syn and TAT-DJ-1; DJ-1 was inactivated by the siRNA
method. On a micromolar scale TAT-a-syn aggregated and triggered neurotoxicity, while on the nanomolar scale it was
neuroprotective against oxidative stress (induced by H2O2 or 6-hydroxydopamine). TAT-DJ-1 increased the expression of
HSP70, while DJ-1 silencing made SK-N-BE cells more susceptible to oxidative challenge, rendering TAT-a-syn neurotoxic at
nanomolar scale, with the appearance of TAT-a-syn aggregates.
Conclusion/Significance: DJ-1 inactivation may thus promote a-syn aggregation and the related toxicity, and in this model
HSP70 is involved in the antioxidant response and in the regulation of a-syn fibril formation.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative, multifactorial
movement disorder affecting about 3% of the population over
65 years [1,2]. To date, six different casual genes linked to rare
familiar forms of PD have been identified, with few evident
functional interactions [3–5]. Consequently, a major question is
the relationship between these proteins whose alteration leads
ultimately to a similar pathology. Genetic modifications in the
proteins coded by the family-PD-linked genes PARK-1 [alias a-
synuclein (a-syn); GenBank: NM_000345; OMIM: #168600] and
PARK-7 (alias DJ-1; GenBank: NM_007262; OMIM: #606324)
cause respectively an autosomal dominant and an autosomal
recessive form of PD [6–9].
A-syn physiologic function is unclear, but the protein is present
in Lewy bodies (LB), a PD hallmark [10]. An a-syn-dependent
etiopathologic hypothesis states that in PD a-syn is able to
aggregate and gain a toxic function, even if the noxious aggregated
form (protofibrillar or fibrillar) is debated [11,12]. Transgenic
models developed to support this hypothesis resulted in mild to
severe phenotypes [13,14]. A-syn gene multiplication has been
associated with familial PD [15,16]. Other data support an
alternative scenario where a-syn aggregation prevents the protein
performing its physiological neuroprotective functions that deal
with chaperone-like activity, dopamine homeostasis and correct
synaptic vesicular trafficking [17–19]. A-syn null mice did not
show a severe phenotype, suggesting that loss of function alone is
not sufficient to explain the pathogenesis [20].
DJ-1 mutations are single-nucleotide substitutions or deletions
leading to a non-functional protein [21,22]. DJ-1 alterations are
more frequent than a-syn mutations; consequently, DJ-1 has been
evaluated as a genetic predisposing factor for sporadic PD though
with mainly negative results [23,24]. Information on DJ-1 function
in the nervous system deals with antioxidant activity [25,26],
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physiology [29,30] and dopamine homeostasis [31,32].
The interaction between a-syn and DJ-1 has been explored in
cellular models of a-syn overexpression, suggesting that DJ-1 is
involved in preventing a-syn toxicity by induction of HSP70
(GenBank NM_005345) [33]. HSP70 was also shown to prevent a-
syn toxicity in vivo and in vitro [34,35] and it was suggested that a-
syn neuroprotective activity depended on HSP70 induction [36].
To clarify the relationship among a-syn, DJ-1 and HSP70 we
developed an in vitro model of oxidative stress in the human
neuroblastoma cell line SK-N-BE, where we transiently altered the
a-syn and DJ-1 concentrations by adding TAT-fused proteins and
by the siRNA approach.
Materials and Methods
Human neuroblastoma SK-N-BE cells
Cells were cultured at 37uC, with 5% CO2 in D-MEM
supplemented with 10% foetal bovine serum (FBS), 2 mM L-
glutamine, 100 IU/mL penicillin and 100 mg/mL streptomycin
(Invitrogen, Carlsbad-CA, USA), in a humidified atmosphere.
Alpha-synuclein and DJ-1: cloning and TAT-fused
proteins generation
Human a-syn full-length cDNA and human DJ-1 full-length
cDNA were cloned starting from a human brain cDNA library
(Clontech, Palo Alto-CA, USA) by RACE-PCR. The amplified
cDNAs were then cloned into pRSET expression vectors (Invitro-
gen, Carlsbad-CA, USA) and fully sequenced. To generate the
fusion proteins TAT-a-syn and TAT-DJ-1 the sequence coding for a
peptide containing the translocation domain of the HIV-1 protein
TAT (underlined) (MRGSHHHHHHGMARGYGRKKRRPASP-
GAS) was inserted in frame before the N-terminal of the
corresponding cDNA. The fusion proteins were then expressed
and purified adapting standard recombinant techniques [37].
Oxidative stress challenge and TAT-fused protein
treatment
To challenge SK-N-BE cells with oxidative stress, 60610
3 cells
were seeded in a 96-well plate and incubated overnight. The day
after, the medium was changed, a freshly prepared H2O2 dilution
(or 6-hydroxydopamine [6-OHDA]) was added (final concentra-
tion H2O2 75 mM; 6-OHDA 50 mM), and the cells were
incubated for 24 h. Viable cells were estimated by erythrosine-
dye exclusion assay or lysed in the presence of a broad-range
protease inhibitor cocktail to obtain a total protein extract. To
perform erythrosine-dye exclusion assay, cells were harvested by
trypsinization and resuspended in complete D-MEM medium. An
aliquot (10 mL) was stained 1:1 (vol/vol) with a 0.05% erythrosine
B-dye solution in PBS and viable cells (uncoloured) were counted
using a cell counting chamber. To verify the protective action of a-
syn (or DJ-1) against oxidative injury, 2–4 h before H2O2 (or 6-
OHDA) was added, the cells were incubated with TAT-a-syn
0.5 mM (or TAT-DJ-1 3 mM) in order to assure that the media
contained the TAT-fused proteins during the oxidative challenge.
To trigger TAT-a-syn toxicity, cells were incubated with TAT-a-
syn 3 mM for 24 h, then viability was assessed by erythrosine-dye
exclusion assay or cells were lysed as described above.
Thioflavin-T binding assay for detection of amyloid
aggregates
SK-N-BE cells were cultured on plastic chamber slides (Nalge
Nunc International-NY, USA), and treated as previously reported,
with TAT-a-syn (0.5–3 mM) for 24–48 h. Then, they were fixed
with 2% paraformaldehyde and incubated 8 min with 0.05%
thioflavin-T solution in PBS. After washing twice with PBS,
fluorescence emission was monitored by a fluorescence microscope
(Olympus Corporation, Tokyo, Japan) coupled to a digital camera
(Olympus Corporation, Tokyo, Japan).
Western blotting
About 25 mg of total protein extract was subjected to gradient
SDS-PAGE electrophoresis (5–12%) and transferred to a nitro-
cellulose membrane (BioRad Laboratories, Hercules-CA, USA).
The membrane was incubated overnight with a primary antibody,
for 1 hour with a horseradish peroxidase-conjugated secondary
antibody (Santa Cruz Biotechnology, Santa Cruz-CA, USA) and
ECL-detected (GE Healthcare, Piscataway-NJ, USA). The
resulting impressed film was quantified using a digital image
analyser (Syngene Corporation, Cambridge, UK).
Immunocytochemistry
30610
3 SK-N-BE cells were cultured on plastic chamber slide,
fixed with 4% paraformaldehyde and permeabilized using 0.5%
Triton-X 100, 0.2% FCS in PBS. Then, they were incubated
overnight at 4uC with a primary antibody diluted 1:100 in
PBS+1% horse serum (HS), followed by a FITC-conjugated
secondary antibody (Jackson Immuno Laboratories, West Grove-
PA, USA) diluted 1:200 in PBS+1% HS. Cells were then analyzed
with a fluorescence microscope coupled to a digital camera
(Olympus Corporation, Tokyo, Japan).
RNA interference
RNA interference was performed as follows: 80610
3 SK-N-BE
cells were seeded in a 24-well plate and grown overnight. The next
day, the medium was replaced with 250 mL of fresh complete
medium and two pre-designed double-strand small-interfering
RNAs (siRNA) against DJ-1 mRNA sequence (siRNA-A sense: 59-
GGG ACCAUAUGAUGUGGUGtt-39; antisense: 59-CACCA-
CAUCAUAUGGUCCCtc-39. siRNA-B sense: 59-GGAGCAG-
GAAAACCGGAAGtt-39; antisense: 59-CUUCCGGUUUUC-
CUGCUCCtt-3) (Ambion, Austin-TX, USA) were added
singularly in 50 mL serum-free Optimem (Invitrogen, Carlsbad-
CA) at 100 nM final concentration using as vehicle SilentFect
liposome formulation (BioRad Laboratories, Hercules-CA) for 24–
96 h, without any other medium change, to achieve DJ-1
downregulation. To prove specific DJ-1 silencing, also a negative
control siRNA was used (CT-), comprised of a 19 bp scrambled
sequence with 39 dT overhangs that has no significant homology
to any known human gene sequence (Ambion, Austin-TX, USA).
Cell viability was then assessed by erythrosine-dye exclusion assay
or cells were lysed in the presence of a broad-range protease
inhibitor to obtain a total protein extract.
Semiquantitative RT-PCR
Semiquantitative RT-PCR was performed starting from 100 ng
of DNA-free total RNA extracted from SK-N-BE cells with a
commercial kit (Qiagen, Valencia-CA, USA) using the following
primers: HSP70 forward: 59-TTT GAC AAC AGG CTG GTG
AAC C-39; HSP70 reverse: 59-GTG AAG ATC TGC GTC TGG
TTG G-39; aldolase-A forward: 59-CGC AGA AGG GGT CCT
GGT GA-39; aldolase-A reverse: 59-CAG CTC CTT CTT CTG
CTC CGG GGT-39. The resulting PCR products were loaded
and quantified on a capillary electrophoresis unit (Agilent
Technologies, Palo Alto-CA, USA) in comparison to a standard
internal marker.
DJ-1/a-Synuclein Interaction
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The following primary antibodies were used to run immuno-
blotting or immunocytochemistry: anti a-syn monoclonal antibody
(Transduction Laboratories, Lexington-KY, USA); anti DJ-1
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz-CA.
USA); anti a-tubulin monoclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz-CA, USA) and anti HSP70 polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz-CA, USA).
Chemicals and reagents
All chemicals were of analytical grade. Where not stated
otherwise, reagents were from Sigma (Sigma Aldrich, St Louis-
MO, USA).
Statistical analysis
All experiments were run at least three times. Statistics was
analyzed using the program StatView ver 5.0. One-way ANOVA
(or two-way ANOVA) was used, followed by Dunnett’s or Tukey’s
post-hoc test. The significance limit was set at p=0.05.
Results
TAT-a-syn and TAT-DJ-1 prevent oxidative stress in SK-N-
BE cells
SK-N-BE cells were exposed to H2O2 or 6-OHDA for 24 h and
neurotoxicity was assessed. To establish the optimal experimental
dosage, we first plotted a dose-response curve [Figure 1A–B]. We
decided to run the ensuing experiments using 75 mMH 2O2 or
50 mM 6-OHDA, that reduced cell viability by about 50%.
To finely tune the a-syn or DJ-1 intracellular concentration, we
incubated cells with the fusion proteins TAT-a-syn and TAT-DJ-
1. First we used Western blotting to plot the kinetics of TAT-a-syn
and TAT-DJ-1 availability inside cells. The basal level of
endogenous a-syn in SK-N-BE cell was negligible (0h lane), while
TAT-a-syn 0.5 mM fusion protein was detectable from 4 h after
addition to the medium, migrated as a doublet around 21KDa and
even if its total amount decreased over time it was still present 48h
after treatment. At difference from a-syn, SK-N-BE expressed DJ-
1 at basal level (0h lane) but after TAT-DJ-1 3 mM addition a
stronger immunoreactive band was detectable starting from 2h
and its level kept almost unchanged till 48h [Figure 1C].
Afterwards, we verified the protective effect of TAT-a-syn or TAT-
DJ-1 against oxidative challenge, performing a dose-response curve.
As shown in Figure 1D,T A T - a-syn protection started from 0.1 mM
in comparison to untreated cells, but the optimal protective
concentration was set at 0.5 mM, where we observed an almost
complete prevention of oxidative stress-induced toxicity. TAT-DJ-1
too was neuroprotective against both H2O2 and 6-OHDA
neurotoxicity [Figure 1E]. Viability increased starting from 1 mM
for 6-OHDA treated cells, and the optimal protective dose against
bothH2O2and 6-OHDA was set at3 mM ,w h e r ew ef o u n dasu r v i v a l
rate that was not statistically different from control.Increasing further
the TAT-DJ-1 concentration did not improve survival rate, even if no
toxicity was detectable up to 5 mM (data not shown). We have also
tried to further increase TAT-a-syn concentration but at doses higher
than 1 mM it reduced cell viability and caused a thioflavin-T positive
reaction, suggesting the appearance of intracellular aggregated forms
of the fusion protein [Figure 1 F–G].
DJ-1 downregulation by siRNA increased SK-N-BE
susceptibility to oxidative challenge
In order to verify how much DJ-1 protected SK-N-BE cells
from oxidative damage, we downregulated endogenous DJ-1
expression by small-interfering RNA (siRNA) technology.
Figure 2A shows a preliminary DJ-1 silencing experiment
assessed by Western blotting, using two independent DJ-1-targeted
siRNAs (siRNA-A and siRNA-B), 20 or 100 nM final concentra-
tion each, for 72 h. Both siRNAs achieved DJ-1 downregulation,
but siRNA-B 100nM was the most effective, as confirmed by blot
quantification [DJ-1/a-tubulin optical density (OD) ratio in
control (mean6SD, n=3): 1.160.1; DJ-1/a-tubulin OD ratio
(mean6SD, n=3) for siRNA-A 100 nM: 0.560.1; DJ-1/a-tubulin
OD ratio for siRNA-B 100 nM (mean6SD, n=3): 0.460.1,
p,0.001 vs control, Tukey’s test]. Consequently, for the ensuing
silencing experiments we decided to use siRNA-B at 100 nM.
Wealsoperformeda specificitycontrolexperimentusinga b-actin
targeted-siRNA that was unable to affect DJ-1 expression, so did a
siRNA negative control (CT-) with no sequence homology to DJ-1
mRNA [Western blot quantification: DJ-1/a-tubulin OD ratio for
control (mean6SD, n=3): 1.060.1; DJ-1/a-tubulin OD ratio
(mean6SD, n=3) for b-actin siRNA 100 nM: 1.060.1; DJ-1/a-
tubulin OD ratio (mean6SD, n=3) for CT- siRNA 100 nM:
0.960.1] [Figure 2B]. The silencing treatment using the lipid
vehiclewasnottoxictocells,withnostatisticallysignificantreduction
incellular viability incomparison to untreated cells (data not shown).
To fully characterize DJ-1 silencing by siRNA-B 100 nM, we
performed a time-course experiment, shown in [Figure 2C]. DJ-1
protein level significantly decreased starting from 72 h and this
reduction was even more evident at 96h, as reported in
Figure 2D. DJ-1 downregulation at 72 h after siRNA treatment
was also independently confirmed by immunocytochemistry,
where a decrease of DJ-1 immunostaining was found in the DJ-
1 siRNA treated-cells [Figure 2E].
Then, we challenged cells with the oxidative agent 72 h after
DJ-1 silencing, in order to be sure to achieve DJ-1 downregulation
in a detectable way. In this condition, SK-N-BE cells were more
susceptible to oxidative damage induced by H2O2 or 6-OHDA,
with a strong reduction in cellular viability that dropped under
25% in comparison to control after H2O2 and under 50% after 6-
OHDA. This effect was specifically due to DJ-1 silencing, as the
treatment with a siRNA negative control (CT-) did not influence
the cell response to oxidative stress [Figure 2F].
To further check the specificity of this DJ-1-silencing effect, we
tried to reverse the DJ-1 silencing by adding TAT-DJ-1 3 mM2 h
before the oxidative treatment. We were able to reproduce the
deleterious effect of DJ-1 silencing (as cell viability of the silenced
groups in presence of oxidative stress was decreased in comparison
to DJ-1 not silenced groups), and when we added TAT-DJ-1 this
completely counteracted the negative effect of H2O2 or 6-OHDA.
The extracellular add of 3 mM recombinant DJ-1 (a purified form
of DJ-1 without the TAT sequence) had no such effect, confirming
that only TAT-DJ-1 entered the plasma membrane and protected
the cells [Figure 2G]. We found the same situation when we
treated cells with a TAT-GFP fusion protein that entered inside
cells but was unable to counteract the deleterious effect of DJ-1
silencing (Figure S1A).
DJ-1 silencing prevents TAT-a-syn protective action and
increases TAT-a-syn dose-dependent toxicity
To explore a possible functional relationship between DJ-1 and
a-syn we silenced DJ-1 expression by siRNA and tested TAT-a-
syn mediated protection against H2O2 or 6-OHDA. As shown in
Figure 3A, TAT-a-syn at nanomolar scale completely antago-
nized H2O2 or 6-OHDA toxicity, but this effect was no longer
detectable in the presence of DJ-1 downregulation by siRNA. In
this situation, cell viability dropped to under 50%, whit a more
pronounced toxicity for H2O2 treatment. This effect was
DJ-1/a-Synuclein Interaction
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e1884Figure 1. TAT-a-syn and TAT-DJ-1 prevent oxidative stress in SK-N-BE cells. (A) Dose-response pattern of the toxic effect of hydrogen
peroxide (H2O2) in SK-N-BE cells. (B) Dose-response curve of 6-hydroxydopamine (6-OHDA) toxicity in SK-N-BE cells. Cells were plated and challenged
by oxidative stress for 24 h and cell viability was assessed by erythrosine-dye exclusion assay; *p,0.05; ***p,0.001 vs control group (0 mMH 2O2 or 6-
OHDA), Dunnett’s post-hoc test. (C) Western blot assessing TAT-a-syn 0.5 mM and TAT-DJ-1 3 mM availability inside SK-N-BE cells. Cells were plated
and incubated in presence of TAT-a-syn or TAT-DJ-1 for the reported time intervals. To demonstrate equal gel loading, a-tubulin immunoreactivity is
also presented. (D) Protective effect of TAT-delivered a-syn and (E) TAT-delivered DJ-1 against oxidative stress. Cells were incubated with increasing
amounts of TAT-a-syn or TAT-DJ-1 2–4 h before the toxic treatment and 24 h later cell viability was assessed by erythrosine-dye exclusion assay;
*p,0.05; **p,0.01 vs control group at the same TAT-a-syn or TAT-DJ-1 concentration (CT, corresponding also to 0 mMH 2O2 or 6-OHDA), Tukey’s
post-hoc test. (F) Toxicity of micromolar amounts of TAT-a-syn. Cells were incubated with increasing concentrations of TAT-a-syn for 24 h and cell
viability was assessed by erythrosine-dye exclusion assay. **p,0.01 vs control group (CT, corresponding to 0 mM TAT-a-syn), Dunnett’s post-hoc test.
(G) Amyloid aggregation of TAT-a-syn 3 mM was detected by thioflavin-T staining after 24 h incubation; a) SK-N-BE control cells; b) SK-N-BE cells
incubated with TAT-a-syn 3 mM. The arrows indicate intracellular thioflavin-T-positive inclusions (magnification 20X).
doi:10.1371/journal.pone.0001884.g001
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1884Figure 2. DJ-1 downregulation by siRNA increases SK-N-BE susceptibility to oxidative challenge. (A) Preliminary Western blotting
experiment aimed at modulating DJ-1 expression by siRNA. Two different siRNAs were tested by exposing SK-N-BE cells to 20 and 100 nM siRNA for
72 h. Each blot lane is representative of a triplicate assay in the same experiment (B) Western blotting assessing the specificity of the proposed
silencing method. SK-N-BE cells were exposed for 72 h to b-actin targeted pre-designed siRNA and to a siRNA negative control (CT-) with no
sequence similarity to DJ-1 mRNA. Each blot lane is representative of a triplicate assay in the same experiment. (C) Silencing DJ-1 expression by
siRNA. Cells were incubated with 100 nM pre-annealed siRNA targeted to DJ-1. Starting 24 h after transfection, DJ-1 protein level was assessed by
Western blotting and quantified by a digital image analyzer. The quantification (D) is representative of one of three independent experiments (n=3
for each point); *p,0.05; **p,0.01 vs control group (siRNA lipid vehicle) at the same time, Tukey’s post-hoc test. (E) DJ-1 silencing was also
independently assessed by immunocytochemisty: a) SK-N-BE control cells exposed for 72 h to siRNA lipid vehicle alone (magnification 10X); b) SK-N-
BE cells incubated for 72 h with 100nM DJ-1 siRNA (magnification 10X). (F) DJ-1 downregulation increases cell susceptibility to oxidative stress. Cells
were silenced for DJ-1 expression for 72 h, then the oxidative stimuli were added for a further 24 h. Cell viability was assessed by erythrosine-dye
exclusion assay. CT-: siRNA negative control; *p,0.05; **p,0.01 vs control group (siRNA lipid vehicle alone); up,0.05; uup,0.01 vs siRNA lipid
vehicle+H2O2 or 6-OHDA alone; Tukey’ post-hoc test. (G) Specific effect of DJ-1 on oxidative stress response. Cells were silenced for DJ-1 expression
for 72 h, then TAT-DJ-1 3 mM or a recombinant DJ-1 at the same concentration (rDJ-1, a purified form of DJ-1 without the TAT sequence) was added
2 h before the oxidative challenge. After 24 h, cell viability was assessed by erythrosine-dye exclusion assay. DJ-1 silencing in the same experiment
was confirmed by Western blotting (not shown); **p,0.01 vs control group (siRNA lipid vehicle alone), up,0.05; uup,0.01 vs siRNA lipid
vehicle+H2O2 or 6-OHDA alone; Tukey’s post-hoc test.
doi:10.1371/journal.pone.0001884.g002
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maintained almost unchanged its protective effect against
oxidative stress in the presence of a siRNA negative control
(CT-) and when the DJ-1 protein level was restored by exogenous
addition of TAT-DJ-1 2h before the oxidative challenge
[Figure 3B].
We noticed another relevant effect of DJ-1 silencing on TAT-a-
syn. In fact, after DJ-1 silencing by siRNA, if TAT-a-syn was
added to cells at 0.5 mM for 24 h, it not only lost its protective
property against oxidative stress but also became toxic in absence
of a deleterious stimulus, triggering by itself cell death in a
significant manner [Figure 3C]. To confirm that this effect was
Figure 3. DJ-1 silencing prevents TAT-a-syn protective action and increases its dose-dependent toxicity. (A) Cells were pre-incubated
with TAT-a-syn 0.5 mM for 2 h. Then, the oxidative stimuli were added for a further 24 h. In the DJ-1 silenced group, before TAT-a-syn treatment, DJ-1
expression was silenced for 72 h. Cell viability was assessed by erythrosine-dye exclusion assay; **p,0.01 vs control group (siRNA lipid vehicle alone),
Tukey’s post-hoc test. (B) Cells were incubated with siRNA negative control (CT-) or with DJ-1 siRNA for 72 h. Then, in the DJ-1 siRNA cells, TAT-DJ-1
3 mM was added to culture medium and after 2 h TAT-a-syn was added to the indicated groups. After 2 h, the oxidative challenge was then carried
out for 24 h. Cell viability was assessed by erythrosine-dye exclusion assay. **p,0.01 vs control group (siRNA lipid vehicle alone), Tukey’s post-hoc
test; #p,0.01, two-way ANOVA for TAT-a-syn (x) TAT-DJ-1. (C) Cells were silenced for DJ-1 expression for 72 h, then TAT-a-syn 0.5 mM was added for
24 h. In the TAT-DJ-1 group, TAT-DJ-1 was added to the culture medium 2 h before TAT-a-syn. CT-: siRNA negative control; **p,0.01 vs control
group (no TAT-a-syn added); up,0.05 vs TAT-a-syn alone; Tukey’s post-hoc test; #p,0.01, two-way ANOVA for TAT-a-syn (x) TAT-DJ-1. (D) Western
blot showing TAT-a-syn higher-molecular-weight immunoreactive bands after DJ-1 silencing. Cells were silenced for DJ-1 expression for 72 h, after
that TAT-a-syn 0.5 mM was added for 24 h. Cell lysates were subjected to gradient SDS-PAGE (5–12%). The arrow indicates the monomeric form of
TAT-a-syn around 20 KDa, while the bracket the presence of higher-molecular-weight immunoreactivity. Also a-tubulin immunoreactivity is shown to
demonstrate equal gel loading.
doi:10.1371/journal.pone.0001884.g003
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of TAT-DJ-1. In this context, TAT-a-syn was no more toxic, a
situation that was replicated when instead of DJ-1 siRNA we used
a no-match siRNA negative control (CT-).
The following step was to assess whether DJ-1 silencing caused
TAT-a-syn 0.5 mM toxicity by modulation of its aggregation state
and if DJ-1 silencing affected total TAT-a-syn availability inside
cells. To this purpose, we used Western blotting to detect TAT-a-
syn aggregates and to quantify intracellular available monomeric
TAT-a-syn [Figure 3D]. Only when cells were treated with DJ-1
siRNA we noticed the appearance of higher-molecular-weight a-
syn immunoreactive bands (around 40–50 KDa), suggesting of
TAT-a-syn aggregation. On the contrary, in presence of siRNA
lipid vehicle alone only the monomeric a-syn band around
20 KDa was detectable. Remarkably, Western blotting quantifi-
cation data supported a statistically significant increase of about
25% of intracellular total monomeric TAT-a-syn in presence of
DJ-1 siRNA [monomeric TAT-a-syn/a-tubulin OD ratio for
siRNA lipid vehicle (mean6SD, n=4): 2.460.2 ; monomeric
TAT-a-syn/a-tubulin OD ratio for DJ-1 siRNA (mean6SD,
n=4): 3.060.2, p,0.02, Student’s t-test].
We also tried to independently confirm TAT-a-syn 0.5 mM
amyloid aggregation in presence of DJ-1 siRNA by thioflavin-T
staining. However, we did not find any positive signal (data not
shown), even if this method was able to clearly detect TAT-a-syn
aggregates [see Figure 1G].
We have also verified an alternative scenario where we tried to
trigger TAT-a-syn 0.5 mM neurotoxicity in SK-N-BE cells by
increasing H2O2 amount (raised to 100 mM) and 6-OHDA
amount (raised to 75 mM) for 24h in order to mimic an increase
of oxidative stress due to DJ-1 depletion. No evident additive toxic
effect of TAT-a-syn was assessed in presence of TAT-a-syn
0.5 mM and H2O2 or 6-OHDA. On the contrary, in 6-OHDA
treated cells a weak but statistically significant neuroprotective
action of TAT-a-syn was still present (Figure S1B).
TAT-DJ-1 affects HSP70 mRNA expression
Previous data suggested that the protective action of TAT-a-syn
against oxidative stress involved an up-regulation of HSP70 [36].
In order to find out whether HSP70 was also involved in the DJ-1-
mediated antioxidant response, we assessed the effect on HSP70
expression of TAT-DJ-1 and DJ-1 silencing by semiquantitative
RT-PCR, using aldolase A (GenBank NM_184041) as internal
standard [Figure 4A]. In the presence of TAT-DJ-1, HSP70
mRNA was about 2.5 times control, and this increase was
statistically significant as reported in the gel quantification graph
[Figure 4B]. Instead, the DJ-1 siRNA treatment or the siRNA
negative control (CT-) treatment had no such effect on HSP70
expression that was similar to the basal level.
Then, we decided to confirm by Western blotting if HSP70
mRNA increase was also detectable at protein level. As shown in
[Figure 4C], in the presence of TAT-DJ-1 the HSP70
immunoreactive band increased about 2 times the control level,
and this increase was statistically significant as assessed by the blot
quantification reported [Figure 4D]. However, HSP70 protein
level kept unchanged after DJ-1 siRNA treatment, whose effect
on its target was clearly detectable as the DJ-1 immunoreactive
band was about half the control, with a statistically significant
reduction of about 50%. The increase of DJ-1 protein level due to
TAT-DJ-1 addition was also evident, with a statistically significant
increase of DJ-1 immunoreactive band of about 1.5 times the
basal level.
These TAT-DJ-1 mediated effect on HSP70 expression was
specific, as when we used an unrelated TAT-GFP fusion protein
no HSP70 increase at protein level was detectable. A similar
pattern was obtained using another TAT-fused control protein
represented by TAT-a-syn(1-97), a C-terminal truncated a-syn
form that we previously showed to enter plasma membrane but
was unable to induce HSP70 in PC12 cell line [36][Figure 4E].
Finally, to verify whether DJ-1-dependent HSP70 upregulation
was relevant for TAT-a-syn protective action, we performed an
experiment where DJ-1 was downregulated by siRNA approach
and cells where incubated with TAT-a-syn 0.5 mM, a neuropro-
tective condition involving HSP70 upregulation [36]. As assessed
by Western blotting in Figure 5A, when we treated cells with
TAT-a-syn 0.5 mM alone for 24h we confirmed an increase of
HSP70 expression of about 40% the basal level. This effect was
statistically significant as reported in the blot quantification graph
[Figure 5B]. On the contrary, when TAT-a-syn 0.5 mM was
added to cells for 24 h after a 72 h DJ-1 silencing, HSP70 increase
was no more detectable and an increase of total intracellular
monomeric TAT-a-syn was confirmed in analogy to Figure 3D
(DJ-1 silencing was effective, as confirmed by blot quantification in
Figure 5B). We were also able to restore HSP70 upregulation by
adding TAT-DJ-1 3 mM before TAT-a-syn 0.5 mM incubation in
SK-N-BE cells silenced for DJ-1 expression (data not shown).
Finally, we verified whether TAT-a-syn 0.5 mM was able to
induce DJ-1 upregulation at protein level, an effect that could in
turn promote HSP70 expression. We were unable to find out a DJ-
1 increase at protein level when we incubated cells with TAT-a-
syn for 24 h (Figure S1C).
Discussion
We analyzed a possible functional relationship between DJ-1
and a-syn in a cellular model of oxidative stress, a detrimental
condition that is believed to play a major role in neurodegener-
ative disorders. Both proteins have been linked to familial early-
onset forms of PD, but it is still not clear why pathogenic mutations
in these two apparently unrelated molecules lead ultimately to the
same clinical features.
DJ-1 role was investigated after increasing its intracellular
expression level by exogenous addition of a TAT-fused recombi-
nant protein, while its expression was downregulated by siRNA.
These experiments outlined a major role of DJ-1 in the antioxidant
response, as its overexpression correlated positively with a survival
outcome. This protective function was not limited to H2O2
challenge but was also clear against 6-OHDA, a neurotoxin whose
noxious effect reproduces what happens in the dopamine-selective
environment of PD neurodegeneration. Moreover, the antioxidant
effect was specific, as neither a recombinant DJ-1 without the
TAT fused-sequence (that was consequently unable to enter the
cell) nor a siRNA negative control (that did not affect the level of
DJ-1 mRNA) prevented the oxidative damage. Starting from these
data, it is reasonable to conclude that one effect of DJ-1
inactivation by genetic alterations is to impair its prevention of
oxidative stress, thus exposing dopaminergic neurons to exogenous
or endogenous deleterious stimuli.
Zhou et al. suggested that DJ-1-mediated protective action
against a-syn (A53T) overexpression ant toxicity involved HSP70
up-regulation, but this mechanism was not reported under
oxidative stress conditions where a DJ-1-dependent increase of
glutathione cellular levels was highlighted [33]. We found an
increase of HSP70 both at mRNA and protein level after DJ-1
overexpression obtained by adding TAT-DJ-1. This effect missed
using TAT-GFP or TAT-a-syn(1-97) fusion proteins, suggesting
that HSP70 increase was not solely due to a generic cell response
to molecular crowding after TAT-mediated protein delivery.
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action, even if in our experiments under oxidative stress condition
we have not directly demonstrate this aspect. Moreover, our data
do not rule out the possible involvement of other DJ-1-mediated
antioxidant mechanisms, like glutathione increase.
We have already demonstrated an antioxidant function of TAT-
administered a-syn in rat PC12 cells, where it prevented H2O2
oxidative damage by raising the HSP70 protein level [36]. Here,
we have extended this protective property to 6-OHDA, providing
evidence that a-syn is an important neuroprotective element
whose deficiency due to aggregation may concur in triggering PD.
An important issue addressed by our experiments was the
possible functional relationship between DJ-1 and a-syn, in order
to verify whether they do indeed belong to the same antioxidant
pathway. When we downregulated DJ-1 expression by siRNA,
TAT-a-syn alone was no longer able to protect cells from the
oxidative damage, suggesting that DJ-1 presence is needed for an
efficient antioxidant response, probably as a consequence of its
Figure 4. TAT-DJ-1 affects HSP70 mRNA expression. A) Digital image of a capillary electrophoresis assessing the effect of DJ-1 on HSP70
mRNA expression. Cells were either incubated with TAT-DJ-1 for 24 h or silenced for DJ-1 expression for 72 h. Then total mRNA was extracted,
reverse-transcribed and amplified to detect HSP70 (550 bp band) and aldolase-A (180 bp band), used as internal control. The bar graph (B) shows the
RT-PCR assay values and is representative of one of three independent experiments (n=4 for each group). CT-: siRNA negative control; **p,0.01 vs
control (siRNA lipid vehicle alone), Tukey’s post-hoc test. (C) Western blot showing HSP70 protein expression. Cells were incubated with either TAT-
DJ-1 for 24h or DJ-1 siRNA for 72 h, then harvested for Western blotting. The bar graph (D) shows the calculated values normalized to a-tubulin as
internal control and is representative of one of three independent experiments (n=3 for each group); ***p,0.001 vs control group (siRNA lipid
vehicle alone), Tukey’s post-hoc test. (E) Western blotting assessing HSP70 expression level in SK-N-BE cells incubated with negative control TAT-fused
proteins. Cells were incubated with TAT-GFP or TAT-a-syn(1-97) for 24 h and then harvested to perform HSP70 immunodetection.
doi:10.1371/journal.pone.0001884.g004
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this condition is deleterious not only directly but also indirectly as
it negatively affects a second cell-protective mechanism based on
a-syn neuroprotective function.
A second, unexpected but relevant consequence of DJ-1
downregulation on TAT-a-syn was that in this situation TAT-a-
syn was not only unable to counteract the oxidative challenge but
it became toxic by itself even in the absence of oxidative stress and
starting from nanomolar intracellular concentration that was
usually protective. As a-syn toxicity is generally considered a
consequence of its aggregation, we verified that when TAT-a-syn
had deleterious properties an aggregation pattern was detectable.
In fact, only in the presence of DJ-1 siRNA we were able to
identify TAT-a-syn oligomeric aggregates by Western blotting.
This DJ-1 effect on TAT-a-syn nanomolar toxicity was specific as
it could not be reproduced by recombinant DJ-1 (a purified form
of DJ-1 without the TAT sequence) or siRNA negative control and
was reversed by addition of TAT-DJ-1 after DJ-1 silencing.
Moreover, when DJ-1 was silenced, TAT-a-syn at nanomolar
scale was unable to induce HSP70 upregulation, an aspect that
might contribute to TAT-a-syn aggregation and toxicity. A clear
molecular mechanism leading to TAT-a-syn aggregation in
presence of DJ-1 silencing by siRNA is not evident by our
experiments. We can rule out that TAT-a-syn toxicity was just a
consequence of increased oxidative stress after DJ-1 downregula-
tion as an increased oxidative insult was unable to trigger TAT-a-
syn 0.5 mM toxicity, thus suggesting that DJ-1 directly modulated
a-syn aggregation properties. However, considering our data
reporting an increased monomeric TAT-a-syn availability inside
cells in presence of DJ-1 siRNA, we can suggest that DJ-1
downregulation might negatively affect TAT-a-syn degradation
pathway, with a consequent TAT-a-syn accumulation that can
promote its self-aggregation. So, in the presence of a reduced
amount of DJ-1 TAT-a-syn aggregation can start at a nanomolar
scale that is normally protective and too low to trigger aggregation
by itself.
The fact that in the same condition we were unable to detect
any amyloid-like aggregates by thioflavin-T staining might depend
Figure 5. DJ-1 silencing prevents TAT-a-syn-mediated HSP70 upregulation. (A) In the DJ-1 silenced group, SK-N-BE cells were silenced for
DJ-1 expression for 72 h, TAT-a-syn 0.5 mM was then added for 24 h and finally cells were harvested for Western blotting to assess HSP70, DJ-1 and
TAT-a-syn immunoreactivity. The graph (B) shows blot quantification for HSP70 and DJ-1 expression using a-tubulin as internal standard (n=3 for
each group); **p,0.01, vs control group (siRNA lipid vehicle alone), Tukey’s post-hoc test.
doi:10.1371/journal.pone.0001884.g005
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immunoreactive bands was limited to molecular weights 40-50
KDa, with no higher-molecular-weight oligomers, suggesting that
larger amyloid fibrils probably require a more concentrated TAT-
a-syn starting substrate. In accordance with this interpretation,
Zhou et al. [33] did find higher-molecular-weight a-syn [A53T]
aggregates but after strong a-syn overexpression due to adenoviral
infection. However, even without large a-syn amyloid aggregates
cell toxicity was evident, in agreement with the hypothesis that the
early step of a-syn fibril formation is responsible for its toxicity.
In relation to PD pathogenesis, an inactivating DJ-1 genetic altera-
tion might first of all prevent its direct antioxidant action but it might
be also important in promoting a-syn aggregation and the related
toxicity, that is accelerated by a pro-oxidant environment [38].
In summary, as schematically depicted in Figure 6, DJ-1 and
a-syn are both involved in the antioxidant response against H2O2
and 6-OHDA and HSP70 is a common downstream mediator of
the antioxidant properties of these two proteins. A direct
mechanistic relationship between a-syn, DJ-1 and HSP70 is not
supported by our data. In fact, TAT-a-syn was able to increase
HSP70 level in presence of DJ-1 but TAT-a-syn was unable to
increase DJ-1 expression that could in turn promote HSP70
upregulation. A possible interpretation could be that DJ-1 and a-
syn promote HSP70 upregulation but at different levels. In fact,
TAT-DJ-1 addition increased HSP70 at mRNA and protein
expression level, at difference from TAT-a-syn that was unable to
modulate HSP70 mRNA, as we have previously demonstrated
[36]. So, it might happen that TAT-a-syn increases HSP70
protein level by a chaperone-like stabilization mechanism or by an
action that reduces HSP70 degradation over time. This might also
explain why in absence of DJ-1 TAT-a-syn was unable to increase
HSP70 at protein level. In fact, when DJ-1 was downregulated
TAT-a-syn formed insoluble aggregates and in this aggregated
form it is likely that it was unable to interact with HSP70 and
stabilize it. More importantly, we showed that DJ-1 expression is
relevant not only for the effect on HSP70 but also in controlling a-
syn function which, when there are only small amounts of DJ-1, is
shifted from a soluble, neuroprotective condition to an aggregated,
neurotoxic context.
In conclusion, DJ-1 and HSP70 might be therapeutic targets in
PD for their role in counteracting oxidative stress and their
involvement in a-syn solubility-related cell function.
Supporting Information
Figure S1
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